PE20010212A1 - Composiciones del peptido a-beta y procesos para producir las mismas - Google Patents
Composiciones del peptido a-beta y procesos para producir las mismasInfo
- Publication number
- PE20010212A1 PE20010212A1 PE2000000521A PE0005212000A PE20010212A1 PE 20010212 A1 PE20010212 A1 PE 20010212A1 PE 2000000521 A PE2000000521 A PE 2000000521A PE 0005212000 A PE0005212000 A PE 0005212000A PE 20010212 A1 PE20010212 A1 PE 20010212A1
- Authority
- PE
- Peru
- Prior art keywords
- peptide
- composition
- solubilize
- refers
- sufficient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13704799P | 1999-06-01 | 1999-06-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20010212A1 true PE20010212A1 (es) | 2001-02-22 |
Family
ID=22475602
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2000000521A PE20010212A1 (es) | 1999-06-01 | 2000-05-31 | Composiciones del peptido a-beta y procesos para producir las mismas |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP1181040A1 (no) |
JP (1) | JP2003519620A (no) |
KR (1) | KR20020016813A (no) |
CN (1) | CN1353615A (no) |
AR (1) | AR024558A1 (no) |
AU (1) | AU5726100A (no) |
BG (1) | BG106249A (no) |
BR (1) | BR0011251A (no) |
CA (1) | CA2374897A1 (no) |
CZ (1) | CZ20014150A3 (no) |
EE (1) | EE200100649A (no) |
HK (1) | HK1045938A1 (no) |
HR (1) | HRP20010901A2 (no) |
IL (1) | IL146575A0 (no) |
IS (1) | IS6182A (no) |
MX (1) | MXPA01012355A (no) |
NO (1) | NO20015859L (no) |
NZ (1) | NZ515744A (no) |
PE (1) | PE20010212A1 (no) |
PL (1) | PL352575A1 (no) |
RU (1) | RU2001135800A (no) |
SK (1) | SK17012001A3 (no) |
TR (1) | TR200103476T2 (no) |
WO (1) | WO2000072870A1 (no) |
ZA (1) | ZA200109704B (no) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
US6743427B1 (en) | 1997-12-02 | 2004-06-01 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
US7790856B2 (en) | 1998-04-07 | 2010-09-07 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US20030147882A1 (en) | 1998-05-21 | 2003-08-07 | Alan Solomon | Methods for amyloid removal using anti-amyloid antibodies |
US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
EP2082749A3 (en) | 2000-07-07 | 2010-06-30 | Bioarctic Neuroscience AB | Prevention and treatment of Alzheimer's disease |
AU1225702A (en) * | 2000-09-19 | 2002-04-02 | Evotec Neurosciences Gmbh | Methods and compounds for treating brain amyloidosis |
US7700751B2 (en) | 2000-12-06 | 2010-04-20 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize β-amyloid peptide |
MY144532A (en) | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
PE20050627A1 (es) | 2003-05-30 | 2005-08-10 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido beta amiloideo |
SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
JP2008523815A (ja) | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミテッド | 認知の改善における使用のためのヒト化アミロイドβ抗体 |
KR101667623B1 (ko) | 2005-11-30 | 2016-10-19 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
PL1954718T3 (pl) | 2005-11-30 | 2015-04-30 | Abbvie Inc | Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał |
CA2630344C (en) | 2006-03-23 | 2015-04-28 | Bioarctic Neuroscience Ab | Improved protofibril selective antibodies and the use thereof |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
EP2124952A2 (en) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
DK2182983T3 (da) | 2007-07-27 | 2014-07-14 | Janssen Alzheimer Immunotherap | Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
MX336196B (es) | 2010-04-15 | 2016-01-11 | Abbvie Inc | Proteinas de union a amiloide beta. |
MX358739B (es) | 2010-08-14 | 2018-09-03 | Abbvie Inc Star | Proteinas de union a amiloide beta. |
GB201113570D0 (en) | 2011-08-05 | 2011-09-21 | Glaxosmithkline Biolog Sa | Vaccine |
SG11201610734RA (en) | 2014-07-10 | 2017-01-27 | Bioarctic Neuroscience Ab | IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES |
CN114957438B (zh) * | 2022-06-28 | 2024-04-02 | 福建亿彤生物科技有限公司 | 用于检测阿尔茨海默病的人Aβ1-42抗原决定簇多肽及制法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0526511B1 (en) * | 1990-04-27 | 1997-05-28 | MCMICHAEL, John | Method and composition for treatment of central nervous systems disease states associated with abnormal amyloid beta protein |
TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
-
2000
- 2000-05-31 PE PE2000000521A patent/PE20010212A1/es not_active Application Discontinuation
- 2000-05-31 AR ARP000102690A patent/AR024558A1/es unknown
- 2000-06-01 CN CN00808374A patent/CN1353615A/zh active Pending
- 2000-06-01 AU AU57261/00A patent/AU5726100A/en not_active Abandoned
- 2000-06-01 EP EP00942668A patent/EP1181040A1/en not_active Withdrawn
- 2000-06-01 SK SK1701-2001A patent/SK17012001A3/sk unknown
- 2000-06-01 CZ CZ20014150A patent/CZ20014150A3/cs unknown
- 2000-06-01 BR BR0011251-8A patent/BR0011251A/pt not_active Application Discontinuation
- 2000-06-01 MX MXPA01012355A patent/MXPA01012355A/es unknown
- 2000-06-01 RU RU2001135800/14A patent/RU2001135800A/ru unknown
- 2000-06-01 NZ NZ515744A patent/NZ515744A/en unknown
- 2000-06-01 KR KR1020017015474A patent/KR20020016813A/ko not_active Application Discontinuation
- 2000-06-01 TR TR2001/03476T patent/TR200103476T2/xx unknown
- 2000-06-01 CA CA002374897A patent/CA2374897A1/en not_active Abandoned
- 2000-06-01 PL PL00352575A patent/PL352575A1/xx not_active Application Discontinuation
- 2000-06-01 IL IL14657500A patent/IL146575A0/xx unknown
- 2000-06-01 JP JP2001511317A patent/JP2003519620A/ja not_active Withdrawn
- 2000-06-01 EE EEP200100649A patent/EE200100649A/xx unknown
- 2000-06-01 WO PCT/US2000/015302 patent/WO2000072870A1/en not_active Application Discontinuation
-
2001
- 2001-11-26 ZA ZA200109704A patent/ZA200109704B/en unknown
- 2001-11-29 IS IS6182A patent/IS6182A/is unknown
- 2001-11-30 NO NO20015859A patent/NO20015859L/no not_active Application Discontinuation
- 2001-12-04 HR HR20010901A patent/HRP20010901A2/hr not_active Application Discontinuation
- 2001-12-20 BG BG106249A patent/BG106249A/xx unknown
-
2002
- 2002-08-23 HK HK02106241.2A patent/HK1045938A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
AU5726100A (en) | 2000-12-18 |
IL146575A0 (en) | 2002-07-25 |
TR200103476T2 (tr) | 2002-04-22 |
KR20020016813A (ko) | 2002-03-06 |
SK17012001A3 (sk) | 2002-06-04 |
PL352575A1 (en) | 2003-08-25 |
NO20015859L (no) | 2002-02-01 |
AR024558A1 (es) | 2002-10-16 |
NZ515744A (en) | 2004-04-30 |
HK1045938A1 (zh) | 2002-12-20 |
BG106249A (en) | 2002-08-30 |
HRP20010901A2 (en) | 2003-04-30 |
ZA200109704B (en) | 2003-02-26 |
IS6182A (is) | 2001-11-29 |
CA2374897A1 (en) | 2000-12-07 |
CZ20014150A3 (cs) | 2002-05-15 |
WO2000072870A1 (en) | 2000-12-07 |
NO20015859D0 (no) | 2001-11-30 |
EP1181040A1 (en) | 2002-02-27 |
CN1353615A (zh) | 2002-06-12 |
EE200100649A (et) | 2003-02-17 |
MXPA01012355A (es) | 2003-06-24 |
JP2003519620A (ja) | 2003-06-24 |
RU2001135800A (ru) | 2003-08-20 |
BR0011251A (pt) | 2002-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20010212A1 (es) | Composiciones del peptido a-beta y procesos para producir las mismas | |
FI80598C (fi) | Foerfarande foer framstaellning av en enzymberedning. | |
AR024074A1 (es) | FRAGMENTO ABETA UNIDO A UN PÉPTIDO PORTADOR PARA PREVENIR O TRATAR ENFERMEDADES ASOCIADAS CON DEPoSITOS AMILOIDES DE ABETA, COMPOSICIONES FARMACÉUTICAS QUE LO CONTIENEN, Y SU USO EN LA PREPARACION DE MEDICAMENTOS. | |
BR0210721A (pt) | Composto, sal ou éster farmaceuticamente aceitável, método para fabricar um composto, e, método para tratar um paciente que tem, ou para evitar que o paciente adquira uma doença ou condição | |
PE84799A1 (es) | Metodos mejorados para el procesamiento de proteina c activada | |
MY129234A (en) | Oral pharmaceutical forms of administration with a delayed action with tramadol. | |
ECSP024352A (es) | Nueva composicion farmaceutica | |
ATE284415T1 (de) | Mutierte variante des insulin-ähnlichen wachstumsfaktor-i (igf-i) | |
EA199900778A1 (ru) | ГЕТЕРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ И ИХ ИСПОЛЬЗОВАНИЕ ДЛЯ ИНГИБИРОВАНИЯ β-АМИЛОИДНОГО ПЕПТИДА | |
ES2162319T3 (es) | Uso del agente quelante clioquinol para la fabricacion de una composicion farmaceutica para el tratamiento de la enfermedad de alzheimer. | |
FR2627696B1 (fr) | Nouvelle forme galenique du fenofibrate | |
ES2168334T3 (es) | Composicion para el tratamiento de la piel. | |
BR9914940A (pt) | Método para aperfeiçoar a farmacocinética de tipranavir | |
BR0212787A (pt) | Composto ou sal farmaceuticamente aceitável do mesmo, métodos de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto ou sal, e, composição farmacêutica | |
SE0002202D0 (sv) | New peptides | |
PA8542901A1 (es) | Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple | |
CO5570658A2 (es) | Composicion y metodo para el tratamiento de la diabetes | |
NZ535032A (en) | Lyophilised, stable pharmaceutical composition containing factor VIII, which comprises trisodium citrate, but is devoid of amino acids | |
AR002018A1 (es) | Derivado de benzotiepina opticamente activo; metodo para producirlo; compuesto opticamente activo de uso en dicho metodo; promotor deosteogenesis, agente para prevenir o tratar enfermedades del hueso, promotor para el tratamiento de la fractura de hueso, metodo de tratamiento y | |
KR970706839A (ko) | 성장호르몬 및 이소루신으로 이루어진 약학적 조성물(a pharmaceutical formulation comprising a growth hormone and isoleucine) | |
DE60135996D1 (de) | Peptidzusammensetzungen zur behandlung periodontaler krankheiten und prävention der hautalterung | |
AU2003277280A8 (en) | Biphenyls and fluorenes as imaging agents in alzheimer's disease | |
DE69420145D1 (de) | Behandlung präkanzeröser läsionen durch muramylpeptide | |
PT833640E (pt) | Composicao farmaceutica contendo lamotrigina | |
AR021241A1 (es) | Inhibidores de proteasas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |